Eli Lilly Foundayo Prescriptions Surge 350% in One Quarter

What happened

Eli Lilly reported that Foundayo, its oral GLP-1 obesity medication, expanded from 8,000 to 36,000 prescribers in a single quarter. Foundayo is differentiated as the only oral GLP-1 approved for anytime dosing, removing the timing restrictions that apply to competing therapies. The prescription data reflects accelerating physician adoption and patient access. Separately, Lilly reported second-quarter revenue of $22.974 billion, up 47.67% year-over-year, and raised its full-year 2026 revenue guidance to $85 to $87 billion. The company's Mounjaro franchise has already generated more than €27 billion in revenue over the previous 12 months, establishing Lilly as the leader in the GLP-1 obesity and diabetes treatment market.

Why it matters

The surge in Foundayo prescribers signals that Lilly is successfully converting physician interest into real-world prescribing behavior, a critical step in turning regulatory approval into commercial revenue. Oral formulations are seen as more convenient than injectables, potentially broadening patient access and adherence. With Lilly already controlling approximately 6 out of 10 U.S. obesity prescriptions, Foundayo's rapid uptake strengthens the company's competitive moat against rivals like Novo Nordisk, whose Wegovy delivers around 14% weight loss compared to Mounjaro's 20%. The expansion also comes as the Medicare GLP-1 Bridge Program covers 20 million eligible Americans at $50 per month, creating a large addressable market. Foundayo's momentum supports Lilly's ability to sustain revenue growth and defend its $1.1 trillion valuation, the highest in the pharmaceutical sector.

Bigger picture

Eli Lilly has become the world's most valuable pharmaceutical company, with a market capitalization approximately five times that of Novo Nordisk and four times that of AstraZeneca. The GLP-1 obesity and diabetes market is experiencing rapid expansion, driven by clinical efficacy and growing payer coverage. Lilly's pipeline includes retatrutide, a triple-receptor agonist that produced 28.3% average weight loss in Phase 3 trials, approaching bariatric surgery outcomes and potentially creating another blockbuster. The company plans to submit a biologics license application for retatrutide in Q1 2027. Analysts have described retatrutide as a potential trillion-dollar drug. Meanwhile, Novo Nordisk reported a 21% year-over-year earnings contraction, underscoring the competitive shift in Lilly's favor. Lilly's stock has gained 69.79% over the past year and trades at a forward price-to-earnings multiple of 34x, which some analysts view as justified given the company's 48% quarterly revenue growth and dominant market position.

What to watch

Investors should monitor Foundayo's prescription growth in future quarters to assess whether the initial surge translates into sustained adoption and revenue contribution. Key upcoming milestones include the Q1 2027 submission of retatrutide's biologics license application and any updates on Medicare coverage expansion or pricing negotiations. Lilly's ability to maintain its 60% share of U.S. obesity prescriptions amid competitive launches will be critical. Quarterly earnings reports will provide visibility into whether the raised 2026 revenue guidance of $85 to $87 billion remains achievable. Analysts have set a consensus price target of $1,310.90, with some bull-case scenarios reaching $1,627, depending on pipeline execution and market share defense.